Protecting People
Worldwide from
Biological Threats

Preparing for Today’s Health Challenges and Tomorrow’s Threats

From global pandemics to bioterrorism attacks, the world faces a variety of health challenges. Emergent supports governments around the world to be ready to address a crisis and help save lives.

GO FORWARD

    A person wearing a full protective suit, gloves, goggles, and a respirator mask is crouched down and writing on a clipboard in an industrial or hazardous environment.

    Why Europe must be prepared for biological threats

    Emergent CEO Joe Papa shares why protecting the EU from biological threats – both intentional and naturally occurring – must remain a top tier issue.

    Learn More

    Glass vials with metal caps move along a conveyor belt in a sterile, modern pharmaceutical manufacturing facility, with machinery visible in the background.

    About Medical Countermeasures

    Emergent develops, manufactures and delivers medications that may be used in the event of a public health emergency like a biological attack or an emerging disease.

    Many Emergent products protect against known bioterrorist threats that have the potential to impact public health and national security.

    Military vehicles and equipment are seen in a dusty yard, with a camouflage truck in the foreground and a large crane unloading a vehicle, while colorful shipping containers are stacked in the background.

    Public-Private Partnerships

    We work with local, regional, and national governments to help ensure the right products are available and that leaders are prepared for various health threats. This includes collaborating to develop stockpiles that stand ready when needed, and working quickly to supply necessary medical countermeasures when the unexpected happens.

    Biological Threats Are A Top National Security Concern

    A national survey found U.S. policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike.

    A brown circle with a quarter segment missing from the upper left, resembling a three-quarters full pie chart, on a black background.

    73%

    of policy opinion leaders believe a biological attack would be easier to carry out than a nuclear one.

    A minimalistic illustration of five human figures, each with half of their body shaded in brown and the other half outlined in black, set against a black background.

    Almost half

    believe a biological attack is more likely to occur (46% biological attack vs. 29% nuclear attack).

    A simple bar chart with three vertical bars of increasing height, each partially filled with red, and a black trend line with three circular points connecting the tops of the bars, on a black background.

    65%

    agree the likelihood of a biological attack is rising in the U.S.

    Learn More

    Addressing Public Health Threats

    For over 25 years, Emergent has been at work protecting people from things we hope will never happen—so we’re prepared just in case they ever do.

    • Emergent supplies medical countermeasures to governments that are establishing national or regional stockpiles to be deployed in the event of an emergency.

    • Emergent’s research programs are creating next-generation solutions to help create a more secure world and support evolving preparedness strategies.

    • Maximum preparedness is best achieved through long-term strategic partnerships and exchanges between industry players and government partners to anticipate the response to a concerning threat.

    • Closer collaboration among various government actors, industry, emergency services, relief organizations, and civil society can be effective, as each has different priorities in preparedness and response strategies.

    Bioterrorism

    Our current portfolio addresses four Category A biological agents – a classification by the U.S. Centers for Disease Control and Prevention that indicates agents considered the highest risk for a biological attack due to potential ease of dissemination and high mortality.

    We also manufacture both clinical and commercial Biosafety Level 2 and Level 3 products for partners through our North American manufacturing network.

    Disease (Agent)Biological Agent CategoryBiosafety Level
    Anthrax (Bacillus anthracis) Category A BSL2 or BSL3
    Smallpox (variola major) Category A BSL4
    Viral hemorrhagic fevers (filoviruses, e.g. Ebola) Category A BSL4
    Botulism (Clostridium botulinum toxin) Category A BSL4